Lightstone Ventures

Acceleron Pharma is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The company successfully completed an IPO in 2013.

#Biopharmaceuticals

Alchemab Therapeutics is using deep learning and cutting-edge science to develop novel drugs for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies and the adaptive immune system.

#Biopharmaceuticals

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians.

#Biopharmaceuticals

ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. The company successfully completed an IPO in 2020 (NASDAQ: ALXO).

#Biopharmaceuticals

Amber Therapeutics was founded in 2021 with a mission to develop an adaptive neuromodulation therapy that aims to be the first and only singular therapy able to treat mixed urinary incontinence (UUI and SUI).

#Medical Technology

Apreo Health is a development stage medical technology company that is developing innovative, globally applicable treatments for pulmonary disease.

#Medical Technology

Ardian is a medical device company developing catheter-based therapies to treat hypertension and related conditions. Ardian was incubated within The Foundry, the premier medical technology incubator, and was acquired by Medtronic (NYSE: MDT) in 2011.

#Medical Technology

Atsena Therapeutics is a clinical-stage gene therapy company focused on developing novel therapeutics to prevent or reverse blindness.

#Biopharmaceuticals

Avidia is a biopharmaceutical company discovering and developing a new class of human therapeutic proteins called Avimer™. The company was acquired by Amgen (NASDAQ: AMGN) in 2006.

#Biopharmaceuticals

Bonito Biosciences is a company working on a novel oligo based platform to develop RNA degraders. It is also developing a cell-specific delivery technology to be applied to its RNA degraders.

#Biopharmaceuticals

Cabochon Aesthetics is a medical device company developing effective, scientific solutions for the aesthetic treatment of cellulite. The company was incubated within The Foundry, the premier medical technology incubator, and was acquired by Ulthera in 2014.

#Medical Technology

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. Its lead product, Cala Trio™, is the only non-invasive prescription therapy for essential tremor and is now available through a unique digital business model of direct-to-patient solutions.

#Medical Technology

Calithera Biosciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company successfully completed an IPO in 2014.

#Biopharmaceuticals

Developing the next generation of percutaneous left ventricular assist devices.

#Medical Technology

Carrick Therapeutics is a biopharmaceutical company pioneering a portfolio of unique, first in class cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour.

#Biopharmaceuticals

Cerevance is a biopharmaceutical company that is taking a novel approach to the discovery and development of therapeutics for CNS and psychiatric diseases utilizing its powerful NETSseq target discovery platform.

#Biopharmaceuticals

Claret Medical is a medical device company developing innovative solutions for cerebral protection during structural heart and vascular interventions. The company was acquired by Boston Scientific (NYSE: BSX) in 2018.

#Medical Technology

Contego Medical is a Raleigh-based medical device company developing a suite of products for the treatment of neurovascular, coronary and peripheral vascular disease.

#Medical Technology

Cyteir Therapeutics is a biopharmaceutical company and a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases. The company successfully completed an IPO in 2021 (NASDAQ: CYT).

#Biopharmaceuticals

Disarm Therapeutics is a biotechnology company that is creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disease-causing disability and disease progression. The company was acquired by Eli Lilly and Company (NYSE: LLY) in 2020.

#Biopharmaceuticals

Elcelyx Therapeutics is a biopharmaceutical company developing therapeutic agents based on the finding that modulation of the neuro-enteroendocrine system of the gut, including L-cells, amplifies the release of hormones such as those that play an important role in glucose regulation.

#Biopharmaceuticals

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based and incisionless surgical technology for the treatment of GERD.

#Medical Technology

FIRE1 is a medical device company developing novel remote monitoring devices to improve patient quality of life and outcomes while lowering overall healthcare costs.

#Medical Technology

FivePrime Therapeutics is a biopharmaceutical company focused on the discovery and development of a complete range of innovative protein and antibody drugs. The company successfully completed an IPO in 2013.

#Biopharmaceuticals

Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated initial human efficacy related to muscle cramping. The company successfully completed an IPO in 2015.

#Biopharmaceuticals

FoldRx Pharmaceuticals is a biopharmaceutical company developing disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The company was acquired by Pfizer (NYSE: PFE) in 2010.

#Biopharmaceuticals

ForSight VISION2 is a medical device company that developed a proprietary ocular punctal plug drug delivery system. The company was acquired by QLT Inc. (NASDAQ: QLTI) in 2007.

#Medical Technology

ForSight VISION4 is a medical device company developing novel drug delivery therapies for the treatment of retinal diseases. The company was incubated within ForSight Labs and was acquired by Roche (OTCQX: RHHBY) in 2017.

#Medical Technology

ForSight VISION5 is a medical device company focused on a novel anterior segment drug delivery program for ophthalmic drugs. The company was incubated within ForSight Labs and was acquired by Allergan (NYSE: AGN) in 2016.

#Medical Technology

Gemini Therapeutics is a precision medicine company developing a broad, multimodal pipeline of first-in-class therapeutics for genetically-defined age-related macular degeneration and rare diseases.

#Biopharmaceuticals

Gynesonics is a medical device company focused on advancing women’s health by developing minimally invasive, transcervical, uterus-preserving and incision-free technologies for diagnostic and therapeutic applications.

#Medical Technology

Hydra, LLC (“Hydra”) is a biopharmaceutical developing drugs targeting novel ion channels for pain, inflammation, and respiratory disease.

#Biopharmaceuticals

Hypnion is a biopharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders such as sleep, wake-alertness disorders and circadian rhythm abnormalities. The company was acquired by Eli Lilly (NYSE: LLY) in 2007.

#Biopharmaceuticals

Mavericks Endo is a build-to-buy project formed in collaboration with Medtronic to develop endovascular grafts for aortic arch aneurysms and dissections.

#Medical Technology

MediSix Therapeutics is an early-stage cell therapy company that is taking a novel approach to develop chimeric antigen receptor (“CAR”) T cells to target T cell lymphoma and leukemia.

#Biopharmaceuticals

MicroVention is a medical device company developing and marketing innovative neuroendovascular technologies for the treatment of vascular diseases in small vessels. The company was acquired by Terumo (TYO: 4543) in 2006.

#Medical Technology

Morphotek is a biopharmaceutical company developing novel classes of biological-based products to treat cancer, inflammation and infectious diseases. The company was acquired by Eisai Inc. (TYO: 4523) in 2007.

#Biopharmaceuticals

Moximed is a medical device company that is developing innovative devices for patients with osteoarthritis of the knee. The company was incubated within the ExploraMed incubator.

#Medical Technology

Nimbus Therapeutics is a biotechnology company focused on designing highly selective and potent medicines to disrupt known drivers of serious diseases. The company was formed using an LLC model. Its lead program was acquired by Gilead Sciences (NASDAQ: GILD) in 2016.

#Biopharmaceuticals

Nuvaira is a medical device company developing novel devices for treating obstructive lung diseases. The company was incubated within The Foundry, the premier medical technology incubator.

#Medical Technology

Orexigen Therapeutics is a biopharmaceutical company developing therapies for the treatment of obesity. The company successfully completed an IPO in 2007.

#Biopharmaceuticals

A NewCo focused on developing novel autoimmune therapies.

#Biopharmaceuticals

Plexxikon is a biotechnology company developing novel small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to develop a portfolio of competitively differentiated therapeutic programs. The company was acquired by Daiichi Sankyo (TYO: 4568) in 2011.

#Biopharmaceuticals

Portola Pharmaceuticals is a biopharmaceutical company developing innovative therapeutics for cardiovascular and autoimmune/inflammatory diseases. The company successfully completed an IPO in 2013.

#Biopharmaceuticals

PowerVision is a medical device company developing a proprietary fluid-controlled accommodating intraocular lens (IOL) technology to restore the vision of youth to millions of middle-aged or elderly individuals. The company was acquired by Alcon (NYSE: ALC) in 2019.

#Medical Technology

Principia Biopharma is a biopharmaceutical company developing novel compounds with enhanced sensitivity, high potency and longer duration of effect. Principia was acquired by Sanofi (NASDAQ: SNY) in 2020.

#Biopharmaceuticals

Promedior is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. The company was acquired by Roche Holding (OTCMKTS: RHHBY) in 2019.

#Biopharmaceuticals

Proteolix is a biopharmaceutical company developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. The company was acquired by Onyx Pharmaceuticals (NASDAQ: ONXX) in 2009.

#Biopharmaceuticals

Proverum is an Irish medical device company founded in 2016 as a spin-off from Trinity College Dublin. The company is developing a novel treatment solution for patients with symptomatic BPH designed to be safely and effectively performed in a doctor’s office setting in a simple procedure under local anaesthesia. LSV invested in 2022 to support the Company through its pivotal trial and pursuit of regulatory approval for the ProVee system in Europe and the US.

#Medical Technology

Psivant Therapeutics uses proprietary molecular simulation, computation and ML to rationally design small molecule drugs for dynamic protein targets of high value in inflammation and immunology.

#Biopharmaceuticals

Ra Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of drugs with the specificity of antibodies and the oral bioavailability of small molecules. The company successfully completed an IPO in 2016.

#Biopharmaceuticals

Relievant Medsystems is a medical device company developing a new, minimally invasive technology that targets the source of chronic low back pain with a simple one-hour treatment.

#Medical Technology

Reprieve Cardiovascular is a medical device company focused on automated fluid management technologies for acute heart failure treatment.

#Medical Technology

Scioderm is a clinical-stage biopharmaceutical company developing innovative therapies to address diseases with high unmet need, including rare diseases. The company was acquired by Amicus Therapeutics (NASDAQ: FOLD) in 2015.

#Biopharmaceuticals

Second Genome is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics identified using microbiome science.

#Biopharmaceuticals

SetPoint Medical is a clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases.

#Medical Technology

Shoulder Innovations, Inc. is a medical device company developing and commercializing an innovative shoulder replacement system which addresses the greatest cause of surgical failure: glenoid loosening. This improved system is expected to improve patient outcomes and reduce overall system costs.

#Medical Technology

Spine Wave is a medical device company developing and marketing novel devices for spine surgery, specifically spinal fusion, vertebral compression fracture repair and nucleus replacement and augmentation.

#Medical Technology

Tagworks Pharmaceuticals, pioneer of the Click-to-Release approach, is a precision therapy company, leveraging its technology platform, which is protected by a broad patent estate, to develop a new standard of care for patients suffering from severe diseases including cancer.

#Biopharmaceuticals

Tallac Therapeutics is a biopharmaceutical company focused on the research and development of CpG-Antibody conjugates intended to stimulate the immune system in the treatment of cancer.

#Biopharmaceuticals

Threshold Pharmaceuticals is a biotechnology company developing therapeutics based on tumor hypoxia, a platform that offers potential to treat most solid tumors. The company successfully completed an IPO in 2005.

#Biopharmaceuticals

Tizona Therapeutics is a clinical-stage immunotherapy company harnessing the power of the immune system to develop treatments for cancer. In 2020, Gilead Sciences (NASDAQ: GILD) purchased an option to acquire ~50% of the company.

#Biopharmaceuticals

Transcend Medical is a medical device company focused on the development of devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. The company was acquired by Alcon (Novartis) (NYSE: NVS) in 2016.

#Medical Technology

Trishula Therapeutics is a clinical stage company dedicated to the development of TTX-030, a first-in-class, anti-CD39 antibody being studied in advanced cancers in multiple indications.

#Biopharmaceuticals

Trotana Therapeutics is a San Diego based biotech company dedicated to the discovery and development of medicines targeting RNA binding proteins.

#Biopharmaceuticals

Twelve is a medical device company developing a novel device for the treatment of chronic cardiovascular disease. The company was incubated within The Foundry, the premier medical technology incubator, and was acquired by Medtronic (NYSE: MDT) in 2015.

#Medical Technology

Vapotherm is a medical device company pioneering Hi-VNI technology, a less invasive form of support for patients in respiratory distress. The company successfully completed an IPO in 2018.

#Medical Technology

Verastem is a biopharmaceutical company bringing breakthroughs in cancer stem cell research into new medicines for the treatment of major cancers, such as breast cancer. The company successfully completed an IPO in 2012.

#Biopharmaceuticals

Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Vigil’s purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. Vigil is utilizing modern neuroscience drug development across multiple therapeutic modalities to deliver precision-based therapies to improve the lives of patients and their families. The company successfully completed an IPO in 2022 (NASDAQ: VIGL).

#Biopharmaceuticals

French Healthtech company developing AI software solutions to assist electrophysiologists during cardiac arrythmia procedures.

#Medical Technology

Willow is a medical device company commercializing a wearable breast pump that allows women to achieve their breastfeeding goals without pressing pause on their own lives. The company, formerly known as NC7, was incubated within ExploraMed.

#Medical Technology

ZELTIQ is a medical device company developing and marketing a non-invasive, office-based procedure that uses Cryolipolysis, a proprietary cooling technology, to eliminate fat. The company successfully completed an IPO in 2011.

#Medical Technology